Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Future treatment landscape of NSCLC

Sanjay Popat • 19 Oct 2018
ESMO 2018
Lung Cancer Non-Small Cell Lung Cancer Pembrolizumab
KEYNOTE-189

Lung cancer is a field full of progress, as exemplified here by Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK. Dr Popat highlights the developments and future treatment landscape in this space, covering immunochemotherapy combinations, precision medicine and biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Sanjay Popat

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals